Revista Española de Cardiología - Suplemento - vol 20 ; fasc B ; 2020

M. Anguita et al. / Rev Esp Cardiol Supl. 2020; 20(B) :1-46 45 248. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271-289. 249. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99:365-375. 250. Haddy N, Diallo S, El-Fayech C, et al. cardiac diseases following childhood cancer treatment: cohort study. Circulation. 2016;133:31-38. 251. Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015;65:2511-2522. 252. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572-1582. 253. Limat S, Daguindau E, Cahn JY, et al. Incidence and risk-factors of CHOP/R-CHOP- related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma. J Clin Pharm Ther. 2014;39:168-174. 254. Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1:72-78. 255. Lopez-Fernandez T, Martin Garcia A, Santaballa Beltran A, et al. Cardio-onco- hematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol. 2017;70:474-486. 256. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89:1287-1306. 257. Wang L, Tan TC, Halpern EF, et al. Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy. Am J Cardiol. 2015;116:442-446. 258. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:3792-3799. 259. Finet JE, Tang WHW. Protecting the heart in cancer therapy. F1000Res. 2018;7. 260. Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768-2801. 261. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911-939. 262. Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14:721-740. 263. Virani SA, Dent S, Brezden-Masley C, et al. Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. 2016;32:831-841. 264. Finet JE. Management of heart failure in cancer patients and cancer survivors. Heart Fail Clin. 2017;13:253-288. 265. Lopez-Fernandez T. SEC-PRIMARIA. Proceso cardio-onco-hematología. Disponible en: https://secardiologiaes/images/institucional/sec-calidad/sec-primaria/ Anexo_II_Recomendaciones_de_enfermeria_al_alta_1_editedpdf. Consultado Feb 2019. 266. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation. 2019;140:31-41. 267. Rodriguez F, Wang Y, Johnson CE, Foody JM. National patterns of heart failure hospitalizations and mortality by sex and age. J Card Fail. 2013;19:542-549. 268. Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391:572-580. 269. Shore S, Grau-Sepulveda MV, Bhatt DL, et al. Characteristics, treatments, and outcomes of hospitalized heart failure patients stratified by etiologies of cardiomyopathy. JACC Heart Fail. 2015;3:906-916. 270. Anguita Sanchez M, Crespo Leiro MG, de Teresa Galvan E, et al. Prevalence of heart failure in the Spanish general population aged over 45 years. The PRICE Study. Rev Esp Cardiol. 2008;61:1041-1049. 271. Barba Martin R, Marco Martinez J, Emilio Losa J, Canora Lebrato J, Plaza Canteli S, Zapatero Gaviria A. Two-year analysis of Internal Medicine activity in the National Health Care System hospitals. Rev Clin Esp. 2009;209:459-466. 272. Ben-Chetrit E, Chen-Shuali C, Zimran E, Munter G, Nesher G. A simplified scoring tool for prediction of readmission in elderly patients hospitalized in internal medicine departments. Isr Med Assoc J. 2012;14:752-756. 273. Mahjoub H, Rusinaru D, Souliere V, Durier C, Peltier M, Tribouilloy C. Long-term survival in patients older than 80 years hospitalised for heart failure. A 5-year prospective study. Eur J Heart Fail. 2008;10:78-84. 274. Shah RU, Tsai V, Klein L, Heidenreich PA. Characteristics and outcomes of very elderly patients after first hospitalization for heart failure. Circ Heart Fail 2011;4:301-307. 275. Wei JY. Age and the cardiovascular system. N Engl J Med . 1992;327:1735-1739. 276. Iyngkaran P, Liew D, Neil C, Driscoll A, Marwick TH, Hare DL. Moving from heart failure guidelines to clinical practice: gaps contributing to readmissions in patients with multiple comorbidities and older age. Clin Med Insights Cardiol. 2018;12:1179546818809358. 277. Chivite D, Franco J, Formiga F. Chronic heart failure in the elderly patient. Rev Esp Geriatr Gerontol. 2015;50:237-246. 278. Oliva F, Mortara A, Cacciatore G, et al. Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. Eur J Heart Fail. 2012;14:1208-1217. 279. Clark RA. Telehealth in the elderly with chronic heart failure: what is the evidence? Stud Health Technol Inform. 2018;246:18-23. 280. Osmanska J, Jhund PS. Contemporary management of heart failure in the elderly. Drugs Aging. 2019;36:137-146. 281. Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36:2576-2584. 282. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587. 283. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-1456. 284. Zhang Y, Fonarow GC, Sanders PW, et al. A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin- converting enzyme inhibitors in heart failure patients age >/= 65 years. Am J Cardiol. 2011;108:1443-1448. 285. Savarese G, Edner M, Dahlstrom U, et al. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. Int J Cardiol. 2015;199:415-423. 286. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-225. 287. Dulin BR, Haas SJ, Abraham WT, Krum H. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am J Cardiol. 2005;95:896-898. 288. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. 289. Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533. 290. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552. 291. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine- isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310. 292. Ouyang AJ, Lv YN, Zhong HL, et al. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol. 2015;115:901-906. 293. Vamos M, Erath JW, Benz AP, Lopes RD, Hohnloser SH. Meta-analysis of effects of digoxin on survival in patients with atrial fibrillation or heart failure: an update. Am J Cardiol. 2019;123:69-74. 294. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652-1658. 295. Englund G, Hallberg P, Artursson P, Michaelsson K, Melhus H. Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med. 2004;2:8. 296. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376: 875-885. 297. Komajda M, Tavazzi L, Swedberg K, et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. Eur J Heart Fail. 2016;18:1182-1189. 298. By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67:674-694. 299. Deschodt M, Van Grootven B, Jeuris A, et al. Geriatric CO-mAnagement for Cardiology patients in the Hospital (G-COACH): study protocol of a prospective before-after effectiveness-implementation study. BMJ Open. 2018;8:e023593. 300. Dharmarajan K, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in older adults. Heart Fail Clin. 2017;13:417-426. 301. Turner G, Clegg A, British Geriatrics Society, Age UK, Royal College of General Practicioners. Best practice guidelines for the management of frailty: a British Geriatrics Society, Age UK and Royal College of General Practitioners report. Age Ageing . 2014;43:744-747. 302. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198. 303. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-699. 304. Palliative Care Outcome Scale (POS). Disponible en: http://pos-pal.org . Consultado 4 Jun 2019. 305. Johnson MJ, Bland JM, Davidson PM, et al. The relationship between two performance scales: New York Heart Association Classification and Karnofsky Performance Status Scale. J Pain Symptom Manage. 2014;47:652-658. 306. Lyons KD, Bakitas M, Hegel MT, Hanscom B, Hull J, Ahles TA. Reliability and validity of the Functional Assessment of Chronic Illness Therapy-Palliative care (FACIT-Pal) scale. J Pain Symptom Manage. 2009;37:23-32.